BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

British Journal of Radiology (2006) 79, S27-S35
© 2006 British Institute of Radiology
doi: 10.1259/bjr/35628509

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jarritt, P H
Right arrow Articles by Visvikis, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jarritt, P H
Right arrow Articles by Visvikis, D

Full paper

The role of PET/CT scanning in radiotherapy planning

P H Jarritt, PhD, FIPEM1, K J Carson, PhD1, A R Hounsell, PhD1 and D Visvikis, PhD2

1 Northern Ireland Regional Medical Physics Agency, Royal Victoria Hospital, Belfast, UK, 2 U650 INSERM, LaTIM, Brest, France

The introduction of functional data into the radiotherapy treatment planning process is currently the focus of significant commercial, technical, scientific and clinical development. The potential of such data from positron emission tomography (PET) was recognized at an early stage and was integrated into the radiotherapy treatment planning process through the use of image fusion software. The combination of PET and CT in a single system (PET/CT) to form an inherently fused anatomical and functional dataset has provided an imaging modality which could be used as the prime tool in the delineation of tumour volumes and the preparation of patient treatment plans, especially when integrated with virtual simulation. PET imaging typically using 18F-Fluorodeoxyglucose (18F-FDG) can provide data on metabolically active tumour volumes. These functional data have the potential to modify treatment volumes and to guide treatment delivery to cells with particular metabolic characteristics. This paper reviews the current status of the integration of PET and PET/CT data into the radiotherapy treatment process. Consideration is given to the requirements of PET/CT data acquisition with reference to patient positioning aids and the limitations imposed by the PET/CT system. It also reviews the approaches being taken to the definition of functional/tumour volumes and the mechanisms available to measure and include physiological motion into the imaging process. The use of PET data must be based upon a clear understanding of the interpretation and limitations of the functional signal. Protocols for the implementation of this development remain to be defined, and outcomes data based upon clinical trials are still awaited.




This article has been cited by other articles:


Home page
Br. J. Radiol.Home page
BJR review of the year - 2006
Br. J. Radiol., March 1, 2007; 80(951): 147 - 151.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2006 by the British Institute of Radiology.